JPRN-UMIN000036038
Recruiting
未知
Efficacy of Ipragliflozin in type 1 diabetic patients - Efficacy of Ipragliflozin in type 1 diabetic patients
Ise Red Cross Hospital Department of Metabolic Diseases0 sites50 target enrollmentMarch 1, 2019
Conditionstype 1 diabetic patients
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- type 1 diabetic patients
- Sponsor
- Ise Red Cross Hospital Department of Metabolic Diseases
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who had ketoacidosis or coma Malignancies or other diseases with poor prognosis eGFR\<60mL/min/1\.73m2
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Efficacy of ipragliflozin on diabetic nephropathy in patients with type 2 diabetesType 2 diabetes with/without diabetic nephropathyJPRN-UMIN000022615Ogawa Red Cross Hospital50
Completed
Not Applicable
Effect of Ipragliflozin, a new oral hypoglycemic agent, on body composition in patients with diabetestype 2 diabetesJPRN-UMIN000014775Keio University School of Medicine, Internal Medicine30
Active, not recruiting
Not Applicable
Treatment of type 1 diabetes with the drug liraglutide. The effects on blood sugar control, and metabolic hormones and function of the brain at low blood sugar levels.Type 1 DiabetesMedDRA version: 14.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2012-002526-67-DKSten Madsbad
Completed
Not Applicable
ong-term effects of ipragliflozin on diabetic nephropathy and blood pressure in patients with type 2 diabetesType 2 diabetes with diabetic nephropathyJPRN-UMIN000031157Ogawa Red Cross Hospital50
Completed
Not Applicable
Efficacy of ipragliflozin on glucose metabolismtype 2 diabetes mellitusJPRN-UMIN000013921Shiraiwa Medical Clinic10